New Vaccinaiton Strategy: Concerns about a rare side effect have forced some countries to adopt a new strategy of immunization against COVID-19 for children. Myocarditis is a rare side effect in children after the second dose of the Kovid-19 vaccine. Myocarditis causes swelling and redness in the heart muscle. According to media reports, authorities in many countries, including England, Norway and Hong Kong, have recommended a single dose of Pfizer-BioNtech vaccine to children aged 12 years and above.

New vaccination strategy for children

The aim of the exercise is to reduce the risk of possible side effects such as myocarditis while giving partial protection against the corona virus. According to the report, the rare reaction seen after the second dose of mRNA vaccine in this age group is myocarditis. Health officials in those countries are particularly concerned about the rising data. They have shown that inflammatory myocarditis of the heart may be more common in adolescents and young adults after vaccination. However, the risk is very low and significant only after the second dose of mRNA vaccine. But the numbers have changed the risk-benefit math in countries where new cases of infection are mostly low.

Single dose recommendation on rare side effects

A Reuters report said that a single dose of the Pfizer-BioNtech vaccine was recommended for 12-17-year-olds last month. The experts took the decision after seeing the reports of side effects like swelling of the heart after the second dose of mRNA vaccine. Officials in England and Norway are also recommending single doses of Pfizer-BioNtech’s vaccine for 12-15-year-olds and have asked to wait for a decision on a second dose until additional data is available. According to the Centers for Disease Control and Prevention, cases of pericarditis and myocarditis occurred mostly in male adolescents and young adults after the second dose of mRNA of the Kovid-19 vaccine compared to the first dose.

Highlighting the report, Dr. Aaron Glatt, spokesman for the Infectious Diseases Society of America, told Fox News, “This new strategy is certainly a worthwhile evaluation. It has both theoretical and practical advantages in terms of effectiveness.” However, he cautioned that there has to be proper research to prove it. He says the standard approach is yet to be demonstrated and analysed. “These reports are rare and the potential benefits of getting the Kovid-19 vaccine outweigh the potential risks of recorditis and myocarditis,” the health agency CDC said on its website.